Riyadh — Mubasher: Almujtama Alraida Medical Company announced that its board of directors had approved the appointment of the chairman, vice chairman, and the formation of several board committees on 1 August 2026.

These appointments follow the results of the Ordinary General Assembly meeting held on 26 July 2026, which elected the board for a new four-year term.

The current session commenced on 1 August 2026 and is scheduled to conclude on 31 July 2030.

The board confirmed Omar Yousef Khojah as Chairman and Fahad Abdullah Al Samih as Vice Chairman.

Additionally, Almujtama Medical formed its Audit Committee, chaired by Maher Abdullah Al Madani, with Karim Bashti and Ahmed Ibrahim Qasim serving as members.

The Nominations and Remunerations Committee was also established, led by Fahad Abdullah Al Samih, with Hamad Hamdan Al Sarie and Abdulghani Mohammed Al Malki as members.

Further resolutions included the appointment of the Board Secretary and the designation of company representatives to the Capital Market Authority (CMA) and the Saudi Tadawul Group.

These representatives will manage all regulatory requirements and obligations under the Capital Market Law and Companies Law.

This disclosure followed a prior announcement issued by Almujtama Medical on 27 July 2026.